Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma
Emanuel Buehrer, Nina Glassée, Michal Kiciński, Oliver John Kennedy, Christian U. Blank, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandalà (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab versus placebo in resected stage III melanoma. , DOI: https://doi.org/10.1016/j.ejcskn.2025.100727.
